Le Lézard18h
First Real-World Outcomes Data for ADSTILADRIN® (nadofaragene firadenovec-vncg) to be Presented at 2025 ASCO Genitourinary Cancers Symposium
Ferring Pharmaceuticals announced today three abstracts featuring ADSTILADRIN® (nadofaragene firadenovec-vncg) will be presented at the 2025 American Society of Clinical Oncologists Genitourinary ...
BioSpace18h
Vir Leans Into Immunology Roots After Flamed-Out COVID Fame
Just a few months after Vir Biotechnology lost an emergency authorization for its COVID-19 antibody, Marianne de Backer ...
What a $2 Million Per Dose Gene Therapy Reveals About Drug Pricing
Robin Fields ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive our biggest stories as ...
FiercePharma14h
Astellas shifts investment focus to later-stage opportunities amid reprioritization
Astellas has invested heavily in novel technologies that are not necessarily the most successful or popular in the industry.
Managed Healthcare Executive13h
Sarepta Announces Positive Results for Elevidys, Gene Therapy for Duchenne
Results show improved functional outcomes for people with Duchenne muscular dystrophy who are ambulatory. Elevidys, which is ...
Ocugen announces dosing completion in Phase 2 ArMaDa clinical trial
Ocugen (OCGN) announced that dosing is complete, ahead of schedule in the Phase 2 portion of the Phase 1/2 ArMaDa clinical trial for OCU410-a ...